Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Jonathan Pol
McMaster University
41Publications
14H-index
801Citations
Publications 41
Newest
Published on Apr 2, 2019in Nature Communications 12.35
Peng Liu38
Estimated H-index: 38
,
Liwei Zhao4
Estimated H-index: 4
+ 31 AuthorsKristina Iribarren8
Estimated H-index: 8
Immunogenic cell death (ICD) converts dying cancer cells into a therapeutic vaccine and stimulates antitumor immune responses. Here we unravel the results of an unbiased screen identifying high-dose (10 µM) crizotinib as an ICD-inducing tyrosine kinase inhibitor that has exceptional antineoplastic activity when combined with non-ICD inducing chemotherapeutics like cisplatin. The combination of cisplatin and high-dose crizotinib induces ICD in non-small cell lung carcinoma (NSCLC) cells and effec...
2 Citations Source Cite
Published on Apr 17, 2019in Nature Communications 12.35
Peng Liu38
Estimated H-index: 38
,
Liwei Zhao4
Estimated H-index: 4
+ 31 AuthorsKristina Iribarren8
Estimated H-index: 8
The original version of this Article contained an error in the spelling of the author Lin Xia, which was incorrectly given as Xia Lin. This has now been corrected in both the PDF and HTML versions of the Article.
Source Cite
Published on Jul 3, 2019in OncoImmunology 5.50
Wei Xie1
Estimated H-index: 1
,
Laura Mondragón18
Estimated H-index: 18
+ 11 AuthorsLaurence Zitvogel72
Estimated H-index: 72
Source Cite
Published on Jul 3, 2019in OncoImmunology 5.50
Sarah Levesque4
Estimated H-index: 4
,
Jonathan Pol14
Estimated H-index: 14
+ 3 AuthorsGuido Kroemer191
Estimated H-index: 191
(UPMC: Pierre-and-Marie-Curie University)
ABSTRACTDietary interventions have a profound impact on whole body metabolism, including oncometabolism (the metabolic features allowing cancer cells to proliferate) and immunometabolism (the catabolic and anabolic reactions that regulate immune responses). Recent preclinical studies demonstrated that multiple dietary changes can improve anticancer immunosurveillance of chemo-, radio- and immunotherapy. These findings have fostered the design of clinical trials evaluating the capacity of dietary...
Source Cite
Published on Apr 1, 2019in Cell Reports 8.03
Valentina Sica10
Estimated H-index: 10
(Paris V: Paris Descartes University),
José Manuel Bravo-San Pedro26
Estimated H-index: 26
(Paris V: Paris Descartes University)
+ 20 AuthorsSylvie Souquere27
Estimated H-index: 27
(Institut Gustave Roussy)
Summary Inhibition of oxidative phosphorylation (OXPHOS) by 1-cyclopropyl-4-(4-[(5-methyl-3-(3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl]pyridin-2-yl)piperazine (BAY87-2243, abbreviated as B87), a complex I inhibitor, fails to kill human cancer cells in vitro . Driven by this consideration, we attempted to identify agents that engage in synthetically lethal interactions with B87. Here, we report that dimethyl α-ketoglutarate (DMKG), a cell-permeable precursor of α...
Source Cite
Published on Mar 4, 2019in OncoImmunology 5.50
Kristina Iribarren8
Estimated H-index: 8
(University of Paris-Sud),
Aitziber Buqué14
Estimated H-index: 14
(University of Paris-Sud)
+ 6 AuthorsGuido Kroemer191
Estimated H-index: 191
(UPMC: Pierre-and-Marie-Curie University)
ABSTRACTThe treatment of breast cancer largely depends on the utilization of immunogenic chemotherapeutics, which, as a common leitmotif, stimulate the exposure of calreticulin (CALR) on the surface of cancer cells, thereby facilitating their recognition by dendritic cells for the uptake of tumor-associated antigens and subsequent antigen cross-presentation to cytotoxic T cells. Breast cancer cells also express the calreticulin antagonist CD47, which inhibits tumor cell phagocytosis and conseque...
Source Cite
Published on Jan 2, 2019in OncoImmunology 5.50
Jonathan Pol14
Estimated H-index: 14
(McMaster University),
Sergio A. Acuna10
Estimated H-index: 10
(UHN: University Health Network)
+ 24 AuthorsBadru Moloo3
Estimated H-index: 3
(UHN: University Health Network)
ABSTRACTMultiple immunotherapeutics have been approved for cancer patients, however advanced solid tumors are frequently refractory to treatment. We evaluated the safety and immunogenicity of a vaccination approach with multimodal oncolytic potential in non-human primates (NHP) (Macaca fascicularis). Primates received a replication-deficient adenoviral prime, boosted by the oncolytic Maraba MG1 rhabdovirus. Both vectors expressed the human MAGE-A3. No severe adverse events were observed. Boostin...
2 Citations Source Cite
Published on Jan 1, 2019
Juliette Humeau6
Estimated H-index: 6
,
Sarah Levesque4
Estimated H-index: 4
+ 1 AuthorsJonathan Pol14
Estimated H-index: 14
2 Citations Source Cite
Published on Dec 2, 2018in OncoImmunology 5.50
Lucillia Bezu8
Estimated H-index: 8
(UPMC: Pierre-and-Marie-Curie University),
Oliver Kepp62
Estimated H-index: 62
+ 6 AuthorsLorenzo Galluzzi88
Estimated H-index: 88
(Paris V: Paris Descartes University)
ABSTRACTPeptide-based anticancer vaccination aims at stimulating an immune response against one or multiple tumor-associated antigens (TAAs) following immunization with purified, recombinant or synthetically engineered epitopes. Despite high expectations, the peptide-based vaccines that have been explored in the clinic so far had limited therapeutic activity, largely due to cancer cell-intrinsic alterations that minimize antigenicity and/or changes in the tumor microenvironment that foster immun...
3 Citations Source Cite
Published on Dec 2, 2018in OncoImmunology 5.50
Jonathan Pol14
Estimated H-index: 14
(UPMC: Pierre-and-Marie-Curie University),
Sarah Levesque4
Estimated H-index: 4
(UPMC: Pierre-and-Marie-Curie University)
+ 12 AuthorsKaren L. Mossman42
Estimated H-index: 42
(McMaster University)
ABSTRACTOncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, w...
2 Citations Source Cite
12345